(1S,2R,3R,5R)-1-tert-butyl-3-[(5-chloropyrazin-2-yl)amino]-2-fluoro-8-azabicyclo[3.2.1]octane-8-carboxylic acid
C16H22ClFN4O2 — CID 155047179
Data last refreshed: (MolForge compound catalog, from PubChem)
About (1S,2R,3R,5R)-1-tert-butyl-3-[(5-chloropyrazin-2-yl)amino]-2-fluoro-8-azabicyclo[3.2.1]octane-8-carboxylic acid
(1S,2R,3R,5R)-1-tert-butyl-3-[(5-chloropyrazin-2-yl)amino]-2-fluoro-8-azabicyclo[3.2.1]octane-8-carboxylic acid (PubChem CID 155047179) has the molecular formula C16H22ClFN4O2 and a molecular weight of 356.83 g/mol. Its IUPAC name is (1S,2R,3R,5R)-1-tert-butyl-3-[(5-chloropyrazin-2-yl)amino]-2-fluoro-8-azabicyclo[3.2.1]octane-8-carboxylic acid.
Molecular Properties
| Compound Name | (1S,2R,3R,5R)-1-tert-butyl-3-[(5-chloropyrazin-2-yl)amino]-2-fluoro-8-azabicyclo[3.2.1]octane-8-carboxylic acid |
|---|---|
| PubChem CID | 155047179 |
| Molecular Formula | C16H22ClFN4O2 |
| Molecular Weight | 356.83 g/mol |
| Exact Mass | 356.14 |
| IUPAC Name | (1S,2R,3R,5R)-1-tert-butyl-3-[(5-chloropyrazin-2-yl)amino]-2-fluoro-8-azabicyclo[3.2.1]octane-8-carboxylic acid |
| SMILES | CC(C)(C)[C@@]12CC[C@H](C[C@@H](Nc3cnc(Cl)cn3)[C@H]1F)N2C(=O)O |
| InChI | InChI=1S/C16H22ClFN4O2/c1-15(2,3)16-5-4-9(22(16)14(23)24)6-10(13(16)18)21-12-8-19-11(17)7-20-12/h7-10,13H,4-6H2,1-3H3,(H,20,21)(H,23,24)/t9-,10-,13-,16-/m1/s1 |
| InChIKey | HRNFBZNZUBHMNF-OMBOPSAGSA-N |
| XLogP | 3.58 |
| TPSA | 78.35 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 24 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 356.83 |
| LogP ≤ 5 | 3.58 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155047179 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.